div class=trans-pagebutton class=gotoPage data-page=1Page 1button div class=trans-imageimg data-url=document2482016pdfe-g-h-k-f-no-12-222016-dc-ct-noc-no-ctsnd352016-rivastigminehtmlpage=1 data-page=1 class=trans-thumb lazyload alt=Page 1: 24_8_2016pdfE G H K F No 12-222016-DC CT NOC No: CTSND352016 Rivastigmine transdermal patch Any report of serious adverse event occurring during clinical trial study to the loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mM8Uw8AAh0BTZud3BwAAAAASUVORK5CYII= data-src=https:reader033fdocumentsusreader033viewer20220518025aebc4747f8b9ad73f8ee500html5thumbnails1jpg width=140 height=200 divdivdiv class=trans-pagebutton class=gotoPage data-page=2Page 2button div class=trans-imageimg data-url=document2482016pdfe-g-h-k-f-no-12-222016-dc-ct-noc-no-ctsnd352016-rivastigminehtmlpage=2 data-page=2 class=trans-thumb lazyload alt=Page 2: 24_8_2016pdfE G H K F No 12-222016-DC CT NOC No: CTSND352016 Rivastigmine transdermal patch Any report of serious adverse event occurring during clinical trial study to the loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mM8Uw8AAh0BTZud3BwAAAAASUVORK5CYII= data-src=https:reader033fdocumentsusreader033viewer20220518025aebc4747f8b9ad73f8ee500html5thumbnails2jpg width=140 height=200 divdiv